Tau (MAPT) Human shRNA Lentiviral Particle (Locus ID 4137)

CAT#: TL311569V

MAPT - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL311569A virus into HEK293 cells. TL311569A virus was prepared using lenti-shRNA TL311569A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL311569B virus into HEK293 cells. TL311569B virus was prepared using lenti-shRNA TL311569B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL311569C virus into HEK293 cells. TL311569C virus was prepared using lenti-shRNA TL311569C and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL311569D virus into HEK293 cells. TL311569D virus was prepared using lenti-shRNA TL311569D and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 4137
• Synonyms: DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; PPND; PPP1R103; TAU
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001123066, NM_001123067, NM_001203251, NM_001203252, NM_005910, NM_016834, NM_016835, NM_016841, NM_173727, BC114948, BC000558, BC032572, BC040444, BC061892, BC071830, BC094805, BC098281, BC099721, BC101936, BC114504
• Summary: 'This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008]'
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).